Health Condition 1: J989- Respiratory disorder, unspecified
Conditions
Interventions
Intervention1: Safoof Damma Haldiwaala: 5 gm to be given orally twice daily for 51 days
Control Intervention1: Salbutamol: 2mg to be given orally twice daily for 51 days
Sponsors
Central Council for Research in Unani Medicine
Eligibility
Inclusion criteria
Inclusion criteria: (1) Patients of Bronchial Asthama for atleast 6 months having following symptoms: wheeze, Shortness of Breath, Chest Tightness and cough that vary over time and in intensity, Expiratory airflow limitation as suggested by a decreased FEV1. (2) Objective evidence for reversible airway obstruction (>=12% and >=200 mL change in FEV1 and/or a 25% and 60 L/min change in PEFR) either spontaneously or after treatment. (3) patients with Asthma Control Questionnaire Score >1.5
Exclusion criteria
Exclusion criteria: The patients of Zeeq-un-Nafas (Bronchial Asthma) with following conditions will be excluded from the study: 1. Patients below 18 years and above 65 years of age., 2. Pregnant and lactating mother 3. FEV1/FVC ratio 4. Patient with other Respiratory Tract Infections, tuberculosis and malignancy. 5. Patients with Presence of chronic cough with expectoration for 2-3 months in each of 2 successive years. 6. Patient with co-morbidities, Diabetes Mellitus, Hepatic, Renal Insufficiency and Heart disease . 7. Patients with Tobacco Smoking. 8. Patient with regular use of oral or systemic corticosteroids for conditions other than Asthma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in ACQ score, Pulmonary function test in cases of Zeeq un NafasTimepoint: 17 DAYS | — |
Secondary
| Measure | Time frame |
|---|---|
| Haematological and biochemical assessment for safety assessmentTimepoint: At baseline and after 51 days | — |
Countries
India
Contacts
Public ContactDr Ahmed Minhajuddin
National Research Institute of Unani Medicine for Skin Disorders
Outcome results
None listed